CRR_Call Tracker

Text/HTML

Text/HTML

ValueProductView

ValueProductPastPerformance

Company NameReco DateReco PriceExit PriceExit Date% ReturnIn days
ITC Ltd. 28/12/2023464.20487.5002/01/2025 5.02% 1 yrs
Britannia Industries Ltd. 27/07/20234,875.805,028.2512/11/2024 3.13% 1 yrs
JSW Steel Ltd. 22/02/2024826.951,003.0026/09/2024 21.29% 217 days
Bajaj Auto Ltd. 22/08/20249,910.0011,930.0017/09/2024 20.38% 26 days
Dr. Reddy's Laboratories Ltd. 26/10/20235,429.306,536.0005/07/2024 20.38% 253 days
Shriram Finance Ltd. 25/04/20242,430.102,955.0028/06/2024 21.60% 64 days
Coal India Ltd. 25/01/2024389.50501.6022/05/2024 28.78% 118 days
Infosys Ltd. 27/10/20221,522.601,411.6019/04/2024 -7.29% 1 yrs
State Bank Of India 25/05/2023581.30782.0505/03/2024 34.53% 285 days
The Indian Hotels Company Ltd. 24/08/2023401.85517.9007/02/2024 28.88% 167 days

CRR_MVC_PastPerformance

Text/HTML

Our Other Trader Products

EasyDNNNews

Rakesh Jhunjhunwala’s portfolio gains 19,19,23,388.25 in just 1 day: Multibagger pharma stock locked in upper circuit on March 19
Kiran Shroff
/ Categories: Trending, Multibaggers

Rakesh Jhunjhunwala’s portfolio gains 19,19,23,388.25 in just 1 day: Multibagger pharma stock locked in upper circuit on March 19

The stock gave multibagger returns of 160 per cent in just 1 year whereas BSE Sensex Index is up by 5 per cent.

On Wednesday, one of the Top Gainers on BSE, shares of Wockhardt Ltd were locked in a 5 per cent upper circuit to Rs 1,421.60 per share from its previous closing of Rs 1,353.95 per share. The stock’s 52-week high is Rs 1,678.60 per share while its 52-week low is Rs 489.20 per share.

Wockhardt operates as a global pharmaceutical and biotechnology entity, specializing in the production of diverse pharmaceutical products including finished dosage formulations, injectables, biopharmaceuticals, and topical treatments. Notably, Wockhardt holds a significant market position, ranking among the top three Indian generic companies in the UK and securing the sixth-largest generic supplier status within the retail and hospital sectors of Ireland. Furthermore, it boasts the distinction of having the number one Methycobalamin brand in India, highlighting its strong presence and market leadership in key therapeutic areas.

DSIJ's DSIJ's ‘Mid Bridge’ service recommends well researched Mid-Cap stocks for smart investing. If this interests you, do download the service details here.

The company has a market cap of over Rs 23,000 crore and as of December 2024, Rakesh Jhunjhunwala’s portfolio owns 28,37,005 shares or a 1.75 per cent stake in the company (now his portfolio is owned by his Rekha Rakesh Jhunjhunwala since December 2020). In just 1 day, Jhunjhunwala’s portfolio gained Rs 19,19,23,388.25 (28,37,005 shares x Rs 67.65 per share gain today).

The stock gave multibagger returns of 160 per cent in just 1 year whereas BSE Sensex Index is up by 5 per cent. Investors should keep an eye on these Small-Cap pharma stocks.

Disclaimer: The article is for informational purposes only and not investment advice. 

Previous Article Price Volume breakout stocks: These stocks likely to be in focus tomorrow!
Next Article Highest Volume in 1-month: Top 10 PSU stocks recorded their highest volume in one-month; watch out!
Print
519 Rate this article:
3.6
Please login or register to post comments.

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR